A Drug Class Back From the Dead?

Before you go, we thought you'd like these...
Before you go close icon

It looks like the anti-nerve growth factors might be able to re-emerge from the Food and Drug Administration clinical-hold graveyard. An FDA advisory panel recommended yesterday that the drugs are worth pursuing further despite the fact that osteoarthritis patients saw a higher rate of joint problems -- the very side effect that landed them on the FDA's naughty list.

The big question: What the heck took so long? The FDA put the first clinical hold on Pfizer's (NYS: PFE) tanezumab in June 2010 and halted the other anti-nerve growth factors being developed by Regeneron Pharmaceuticals (NAS: REGN) , Sanofi (NYS: SNY) , AstraZeneca (NYS: AZN) , and Johnson & Johnson (NYS: JNJ) by the end of that year. I'm all for keeping patients safe, but an earlier consult of the advisory panel sure would have been helpful for the companies and their investors -- it's not like the patent clock stops when drugs are put on clinical hold.

The FDA doesn't have to follow the advice of the panel of outside experts, but with such an overwhelming majority saying the anti-NGF drugs are worth pursuing, I'd have a hard time seeing the FDA continuing their hard-line stance. The FDA will likely put some restrictions on the trials when they resume, such as not taking the anti-NGF drugs with another class of pain relievers and pulling patients off the drugs early if it appears they aren't working.

Coming off a clinical hold is a necessary first step to getting the drugs approved, but Pfizer and friends aren't out of the woods yet. Efficacy data on tanezumab, the furthest along of the anti-NGF drugs, looks pretty good. There was even a theory that the pain was relieved so much in the osteoarthritis patients that they were overusing their joints, which was causing the apparent side effect. But the risk-benefit analysis -- always a subjective decision by the agency -- can only be determined when all the data is in.

Given their history, if tanezumab or the other drugs get approved, they'll likely only be used as a second- or third-line therapy when other pain medications aren't working. There's money to be made as a last-resort treatment, but not at the blockbuster levels expected a few years ago.

Investing for retirement doesn't have to be painful. The Fool has three stock suggestions to help you retire rich. You can see their names and the reasons Fool analysts like them so much in the Fool's new free report. Click here to get your copy today.

At the time this article was published Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Pfizer, as well as creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners